Incyte And Merck & Co. Expand Clinical Collaboration To Include Phase 3 Study Investigating The Combination Of Epacadostat With Keytruda (Pembrolizumab) As First-Line Treatment For Advanced Melanoma

WILMINGTON, Del. & KENILWORTH, N.J.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the expansion of the companies’ ongoing clinical collaboration to include a Phase 3 study evaluating the combination of epacadostat, Incyte’s investigational selective IDO1 inhibitor, with Keytruda® (pembrolizumab), Merck’s anti-PD-1 therapy, as first-line treatment for patients with advanced or metastatic melanoma. The Phase 3 study, which is expected to begin in the first half of 2016, will be co-funded by Incyte and Merck.

Help employers find you! Check out all the jobs and post your resume.